Does RBC Storage Age Effect Inflammation, Immune Function and Susceptibility to Transfusion Associated Microchimerism in Critically Ill Patients? Adverse Effects of RBC Storage in Critically Ill Patients
Abstract
Critically ill patients are specifically at risk of adverse effects resulting from the use of RBCs of increased storage age. A large multicenter randomized controlled trial in 30 Canadian centers of 2500 critically ill patients called the Age of Blood Evaluation (ABLE) trial has been completed. In this trial of critically ill patients, which included patients with traumatic injuries, study groups were randomized to either RBCs of < 8 days storage time or standard RBC storage time. The primary outcome of this trial is 90 day mortality. Secondary outcomes include severity of multiple organ dysfunction syndrome, serious thrombotic events and nosocomial infections, and ICU and hospital length of stay. Prospective clinical studies investigating the mechanisms and clinical outcomes associated with increased or decreased RBC storage age in critically ill patients including traumatic injury have not been performed. The ABLE study presents a unique and probably one-time opportunity to investigate mechanisms in the context of clinical outcomes for well-characterized study groups. Our ancillary study was designed to determine specific mechanisms of adverse effects related to the RBC storage age in transfused critically ill patients enrolled in the ABLE study. Specifically we determined if the RBC unit storage time affects patient s immune function, inflammation, coagulation, microparticle concentrations and microchimerism.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2015
- Accession Number
- ADA619403
Entities
People
- Philip C Spinella
- Philip J Norris